ReWalk Robotics (LFWD) and The Competition Critical Review
ReWalk Robotics (NASDAQ:LFWD – Get Free Report) is one of 48 publicly-traded companies in the “Surgical appliances & supplies” industry, but how does it contrast to its rivals? We will compare ReWalk Robotics to related companies based on the strength of its dividends, institutional ownership, valuation, profitability, risk, analyst recommendations and earnings.
Earnings & Valuation
This table compares ReWalk Robotics and its rivals gross revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| ReWalk Robotics | $13.85 million | -$22.13 million | -1.93 |
| ReWalk Robotics Competitors | $1.28 billion | $114.74 million | 23.70 |
ReWalk Robotics’ rivals have higher revenue and earnings than ReWalk Robotics. ReWalk Robotics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Profitability
This table compares ReWalk Robotics and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ReWalk Robotics | -159.76% | -28.19% | -23.29% |
| ReWalk Robotics Competitors | -64.23% | -69.97% | -15.40% |
Volatility and Risk
ReWalk Robotics has a beta of 1.99, indicating that its share price is 99% more volatile than the S&P 500. Comparatively, ReWalk Robotics’ rivals have a beta of 0.90, indicating that their average share price is 10% less volatile than the S&P 500.
Analyst Ratings
This is a summary of recent ratings and recommmendations for ReWalk Robotics and its rivals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ReWalk Robotics | 0 | 0 | 1 | 0 | 3.00 |
| ReWalk Robotics Competitors | 310 | 987 | 1798 | 96 | 2.53 |
ReWalk Robotics currently has a consensus price target of $21.00, suggesting a potential upside of 279.75%. As a group, “Surgical appliances & supplies” companies have a potential upside of 7.40%. Given ReWalk Robotics’ stronger consensus rating and higher possible upside, research analysts plainly believe ReWalk Robotics is more favorable than its rivals.
Insider & Institutional Ownership
26.8% of ReWalk Robotics shares are owned by institutional investors. Comparatively, 44.5% of shares of all “Surgical appliances & supplies” companies are owned by institutional investors. 2.1% of ReWalk Robotics shares are owned by insiders. Comparatively, 9.4% of shares of all “Surgical appliances & supplies” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Summary
ReWalk Robotics rivals beat ReWalk Robotics on 8 of the 13 factors compared.
About ReWalk Robotics
ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes robotic exoskeletons for individuals with mobility impairments or other medical conditions in the United States, Europe, the Asia-Pacific, and Africa. The company offers ReWalk Personal and ReWalk Rehabilitation for spinal cord injuries and everyday use by paraplegic individuals at home and in communities; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke in the clinical rehabilitation environment; and MyoCycle and MediTouch tutor movement biofeedback devices for use at home or in clinic. It markets and sells its products directly to third party payers; institutions, including rehabilitation centers; and individuals, as well as through third-party distributors. The company was formerly known as Argo Medical Technologies Ltd. ReWalk Robotics Ltd. was incorporated in 2001 and is headquartered in Yokneam Illit, Israel.
Receive News & Ratings for ReWalk Robotics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for ReWalk Robotics and related companies with MarketBeat.com’s FREE daily email newsletter.
